Company

Percheron Therapeutics Limited

Biotechnology Research Melbourne, Victoria, Au 9 employees

Employees: 9
Contacts: 3
Emails: 3
Phones: 1

antisense.com.au LinkedIn

Percheron Therapeutics Limited Overview

Headquarters: Melbourne, Victoria, Au
Website: antisense.com.au
Industry: Biotechnology Research
Employees: 9
Founded: 2000
NAICS: Research and Development in Biotechnology (except Nanobiotechnology)

Keywords

Recce Pharmaceuticals Ltd

About Percheron Therapeutics Limited

Percheron Therapeutics Limited (ASX: PER) is an international biotechnology company focused on the development of novel therapies for rare diseases. The company’s lead program is ATL1102, an antisense oligonucleotide targeting the CD49d receptor. ATL1102 is currently the subject of an ongoing international phase IIb clinical trial for the treatment of non-ambulant patients with Duchenne Muscular Dystrophy (DMD), for which data is expected in 2H CY2024. The drug has previously reported promising results from an exploratory phase IIa study in the same population and has been awarded orphan drug designation (ODD) and rare pediatric disease designation (RPDD) by the US FDA. For more information, please contact info@PercheronTx.com.

Percheron Therapeutics Limited Contact Details

People in AeroLeads: 4
With contact data: 3
Email contacts: 3; 75.0% coverage
Phone contacts: 1; 25.0% coverage

Percheron Therapeutics Limited Org Chart

Sample employees and titles

Name	Title	Location	Contact
Andrew Mckenzie	Clinical Development Director	Greater Melbourne Area, Australia	Email
Gil Price, M.d.	President and CEO Neurobo		View
Louise Tremper	Senior Clinical Project Manager	Dookie, Victoria, Australia	Email
Deborah Ambrosini	Chief Financial Officer and Company	Melbourne, Victoria, Australia	Email Phone